By Derek N. Cunningham, OD

Although mild to moderate ptosis is common, affecting about 12% of the population older than 50,1,2 many eye care specialists are hesitant to engage these patients. Until now, surgery—which is not right for all patients and carries risks including infection and under- or over-correction—was the only effective treatment.3 Upneeq (oxymetazoline hydrochloride 0.1%; Osmotica) represents the only FDA-approved

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.